97 related articles for article (PubMed ID: 9212047)
1. HLA-A2402-restricted and tumor-specific cytotoxic T lymphocytes from tumor-infiltrating lymphocytes of a child with Wilms' tumor.
Nagai K; Yamada A; Eguchi H; Kato H; Itoh K
Pediatr Res; 1997 Jul; 42(1):122-7. PubMed ID: 9212047
[TBL] [Abstract][Full Text] [Related]
2. Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer.
Gohara R; Nakao M; Ogata Y; Isomoto H; Oizumi K; Itoh K
Jpn J Cancer Res; 1997 Feb; 88(2):198-204. PubMed ID: 9119749
[TBL] [Abstract][Full Text] [Related]
3. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Seki N; Hoshino T; Kikuchi M; Hayashi A; Itoh K
Cell Immunol; 1997 Feb; 175(2):101-10. PubMed ID: 9023415
[TBL] [Abstract][Full Text] [Related]
4. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
5. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA
J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379
[TBL] [Abstract][Full Text] [Related]
6. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer.
Hoshino T; Seki N; Kikuchi M; Kuramoto T; Iwamoto O; Kodama I; Koufuji K; Takeda J; Itoh K
Int J Cancer; 1997 Mar; 70(6):631-8. PubMed ID: 9096641
[TBL] [Abstract][Full Text] [Related]
7. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma.
Gaudin C; Kremer F; Angevin E; Scott V; Triebel F
J Immunol; 1999 Feb; 162(3):1730-8. PubMed ID: 9973436
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
[TBL] [Abstract][Full Text] [Related]
9. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
10. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F
Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
[TBL] [Abstract][Full Text] [Related]
11. HLA class I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers.
Toh U; Yamana H; Nakao M; Imai Y; Seki N; Takasu H; Kaneshige T; Fujita H; Shirouzu K; Itoh K
Cell Immunol; 1997 May; 177(2):137-43. PubMed ID: 9178640
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
13. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
[TBL] [Abstract][Full Text] [Related]
14. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
[TBL] [Abstract][Full Text] [Related]
15. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
Peoples GE; Goedegebuure PS; Andrews JV; Schoof DD; Eberlein TJ
J Immunol; 1993 Nov; 151(10):5481-91. PubMed ID: 8228240
[TBL] [Abstract][Full Text] [Related]
16. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
17. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma.
Nakao M; Yamana H; Imai Y; Toh Y; Toh U; Kimura A; Yanoma S; Kakegawa T; Itoh K
Cancer Res; 1995 Oct; 55(19):4248-52. PubMed ID: 7671230
[TBL] [Abstract][Full Text] [Related]
18. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
19. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
